NewCo Opportunity: Looking for seed capital willing to join us in our mission to hugely reduce the time & cost associated to stroke rehabilitation.

Despite undergoing rehabilitation, over 60% of stroke survivors continue to experience mobility impairments, which significantly diminish their quality of life and impose substantial costs on healthcare systems. To alleviate the economic impact of stroke, enhancing the effectiveness of rehabilitation is a promising approach—especially given the current limitations. Presently, treatment decisions rely heavily on clinical expertise, and patient progress is rarely monitored using objective metrics.

We propose the development of an intelligent software platform that integrates clinical data with inputs from wearable devices and stroke-specific AI models. This system aims to provide deeper insights into patient recovery, support personalized treatment planning, and improve clinical decision-making. Agilbiomech’s platform will be the first to combine clinical and wearable data, to tune AI models to stroke-specific impairments, and to be able to follow and understand the evolution of patients throughout rehabilitation.

The product is modularly built around an information system integrated with an AI-driven component. We have already developed a working alpha prototype of the information system and are now seeking seed funding to complete the MVP and validate it through pilot testing with early clinical partners, with whom we are already in contact. Additional funding will accelerate the development of the AI components, supporting the data collection necessary to finalize the training database for our models.

AgilBiomech is a spin-off initiative originating from the BioRobotics Group, supported by both national and European research programs. The completion of the MVP will mark a key milestone in the spin-off’s formal launch and promote the integration of our technology into clinical settings by 2026, with the first commercial sale anticipated within 18 months.